Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
A Phase II trial of an intravenous preparation of Hexamethylmelamine was performed in ovarian cancer. Patients who had received prior Platinum based chemotherapy and had measurable disease were eligible. Among 15 evaluable patients, there were no objective responses. Two patients did show clinical and laboratory evidence of improvement. Toxicity was predominantly nausea and vomiting with minimal other toxicity. This intravenous form of Hexamethylmelamine has not shown meaningful activity in ovarian cancer patients who have failed prior platinum treatment.
Hauge
M D
MD
Section of Hematology and Medical Oncology, Mayo Clinic Jacksonville, Florida.
Long
H J
HJ
Hartmann
L C
LC
Edmonson
J H
JH
Webb
M J
MJ
Su
J
J
D006585:Altretamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D006585:Altretamine